[{"address1": "9390 Towne Centre Drive", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 779 3100", "website": "https://poseida.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.", "fullTimeEmployees": 330, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark J. Gergen J.D.", "age": 60, "title": "Executive Chairman of the Board", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 961797, "exercisedValue": 0, "unexercisedValue": 174418}, {"maxAge": 1, "name": "Dr. Kristin  Yarema Ph.D.", "age": 52, "title": "President, CEO & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 711986, "exercisedValue": 0, "unexercisedValue": 61459}, {"maxAge": 1, "name": "Ms. Johanna M. Mylet CPA", "age": 35, "title": "Chief Financial Officer", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Loren  Wagner", "title": "Chief Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristin  Martin", "title": "Chief People & Administration Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Chapman", "title": "Senior VP of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Harry J. Leonhardt Esq., J.D.", "age": 66, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 630233, "exercisedValue": 0, "unexercisedValue": 25579}, {"maxAge": 1, "name": "Dr. Devon J. Shedlock Ph.D.", "title": "Chief Scientific Officer of Cell Therapy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa  Portale", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey  W. Winkelman J.D., Ph.D.", "title": "Senior VP & Chief Patent Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.71, "open": 2.74, "dayLow": 2.61, "dayHigh": 2.755, "regularMarketPreviousClose": 2.71, "regularMarketOpen": 2.74, "regularMarketDayLow": 2.61, "regularMarketDayHigh": 2.755, "beta": 0.456, "forwardPE": -1.5310735, "volume": 412817, "regularMarketVolume": 412817, "averageVolume": 712835, "averageVolume10days": 782080, "averageDailyVolume10Day": 782080, "bid": 2.69, "ask": 2.72, "bidSize": 200, "askSize": 200, "marketCap": 262675424, "fiftyTwoWeekLow": 1.54, "fiftyTwoWeekHigh": 4.27, "priceToSalesTrailing12Months": 4.05971, "fiftyDayAverage": 2.8992, "twoHundredDayAverage": 2.712025, "currency": "USD", "enterpriseValue": 134706528, "profitMargins": -1.9076401, "floatShares": 63981940, "sharesOutstanding": 96928200, "sharesShort": 4048750, "sharesShortPriorMonth": 3835086, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.042, "heldPercentInsiders": 0.33768, "heldPercentInstitutions": 0.47245, "shortRatio": 7.33, "shortPercentOfFloat": 0.0582, "bookValue": 1.084, "priceToBook": 2.5, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -123430000, "trailingEps": -1.37, "forwardEps": -1.77, "pegRatio": -0.61, "enterpriseToRevenue": 2.082, "enterpriseToEbitda": -1.087, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "PSTX", "underlyingSymbol": "PSTX", "shortName": "Poseida Therapeutics, Inc.", "longName": "Poseida Therapeutics, Inc.", "firstTradeDateEpochUtc": 1594387800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "291e20e1-54d3-33de-96cd-b23bf8be3533", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.71, "targetHighPrice": 20.0, "targetLowPrice": 10.0, "targetMeanPrice": 14.0, "targetMedianPrice": 12.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 212202000, "totalCashPerShare": 2.199, "ebitda": -123890000, "totalDebt": 85423000, "quickRatio": 3.102, "currentRatio": 3.176, "totalRevenue": 64703000, "debtToEquity": 82.374, "revenuePerShare": 0.717, "returnOnAssets": -0.25871, "returnOnEquity": -0.84745, "freeCashflow": -40724376, "operatingCashflow": -92167000, "revenueGrowth": 1.487, "grossMargins": -1.42295, "ebitdaMargins": -1.9147501, "operatingMargins": -1.03657, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-10"}]